North America Type 2 Diabetes Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

North America Type 2 Diabetes Market Overview

The North America type 2 diabetes market is expanding with the increasing burden of type 2 diabetes, rising demand for effective glycemic control, and growing adoption of advanced pharmacological therapies. The market is being supported by the increasing use of GLP-1 receptor agonists, SGLT2 inhibitors, insulin therapies, and other modern diabetes treatments, alongside greater emphasis on personalized and long-term disease management. Rising healthcare expenditure, favorable access to innovative therapies, and growing awareness of diabetes-related cardiovascular and renal complications are further supporting market expansion across the region. The market is poised to reach USD 34.57 Billion by 2035.

North America Type 2 Diabetes Market Growth Analysis and Key Influencers

North America Type 2 Diabetes Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

North America Type 2 Diabetes Market Growth Drivers

Rising Demand for Advanced Diabetes Therapies Supports Market Expansion

The increasing prevalence of type 2 diabetes and growing demand for effective pharmacological management are supporting the adoption of advanced glucose-lowering therapies across North America. For instance, in January 2023, the U.S. FDA approved Brenzavvy (bexagliflozin), an SGLT2 inhibitor indicated to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. The approval expanded the range of SGLT2 inhibitor treatment options available in the U.S. market. Continued introduction of newer therapies is expected to strengthen treatment options and support market growth.

North America Type 2 Diabetes Market Restraints

Supply Constraints for High-Demand Diabetes Therapies May Limit Market Expansion

Supply shortages of widely used diabetes therapies may create treatment-access challenges and constrain market growth. For instance, Health Canada reported that Ozempic, Trulicity, and Mounjaro experienced supply issues, with high global demand contributing to shortages. Health Canada's review of the 2023–2024 fiscal year also reported that Ozempic was in shortage from August 2023 to February 2024 due to worldwide demand increases. Such supply constraints can affect treatment continuity and may require healthcare providers to consider alternative therapies.

North America Type 2 Diabetes Market Opportunities

Expansion of GLP-1-Based Therapies Creates New Growth Opportunities

The expanding clinical use of GLP-1 receptor agonists and related incretin therapies is creating new opportunities in the North American type 2 diabetes market. For instance, in December 2024, the U.S. FDA approved the first generic version of Victoza (liraglutide), a GLP-1 receptor agonist indicated to improve glycemic control in patients with type 2 diabetes. The FDA noted that GLP-1 medicines were experiencing shortages and highlighted the potential of complex generics to improve access to these therapies. The expansion of branded and generic GLP-1 treatment options is expected to support broader patient access and create additional market opportunities.

North America Type 2 Diabetes Market Trends

Some of the notable trends in the market are increasing adoption of GLP-1 receptor agonists, growing use of SGLT2 inhibitors, expansion of combination therapies, and increasing focus on weight management alongside glycemic control.

Growing Adoption of GLP-1 and Dual GIP/GLP-1 Therapies Is Likely to Enhance Market Growth

The market is witnessing increasing adoption of incretin-based therapies that address both glycemic control and broader metabolic outcomes. For instance, in November 2023, the U.S. FDA approved Zepbound (tirzepatide) for chronic weight management in adults with obesity or overweight and at least one weight-related condition, including type 2 diabetes. Tirzepatide was already approved under the brand name Mounjaro for improving blood glucose levels in adults with type 2 diabetes. The expansion of tirzepatide indications highlights the increasing convergence of diabetes and obesity management and is expected to influence treatment patterns in the type 2 diabetes market.

North America Type 2 Diabetes Market Share

GLP-1 Receptor Agonists Segment Is Positioned to Lead the Drug Class-Based Market

The market is segmented by drug class into insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and others. Among these, GLP-1 receptor agonists are positioned to maintain a leading position, supported by increasing utilization for type 2 diabetes management and their expanding role in weight management and cardiometabolic care. The increasing use of these therapies is evident in Canada, where Health Canada reported that approximately 7.1 million prescriptions for GLP-1 receptor agonists were dispensed in 2023. The continued expansion of GLP-1-based treatment and development of additional formulations is expected to strengthen the segment during the forecast period.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

North America Type 2 Diabetes Market Analysis by Region

The countries included in the report are the United States and Canada. Among these countries, the United States is expected to lead, supported by the country's large type 2 diabetes patient population, extensive healthcare infrastructure, and rapid adoption of innovative diabetes therapies. Recent regulatory activity further demonstrates the strength of the U.S. treatment landscape. For instance, the FDA approved Brenzavvy in January 2023, Zepbound in November 2023, and the first generic liraglutide in December 2024, expanding treatment options across SGLT2 and GLP-1-related therapies. Canada also represents an important market, with the government introducing legislation in February 2024 for the first phase of national universal pharmacare covering a range of diabetes medications.

Leading Players in the North America Type 2 Diabetes Market

North America Type 2 Diabetes Market Segmentation

Key Questions Answered in the North America Type 2 Diabetes Market Report

• What was the North America type 2 Diabetes market value in 2025?
• What is the North America type 2 Diabetes market forecast outlook for 2026-2035?
• What are the major factors aiding the North America type 2 Diabetes market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major North America type 2 diabetes market trends?
• Which drug class is expected to dominate the market segment?
• Which route of administration is projected to lead the market segment?
• Which distribution channel is anticipated to drive the market segment?
• Who are the key players involved in the North America type 2 Diabetes market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth consultations with healthcare providers, endocrinologists, diabetes specialists, key opinion leaders, pharmaceutical industry experts, and healthcare decision-makers to assess treatment patterns, disease management approaches, therapeutic adoption, unmet needs, and purchasing considerations across North America.
• Secondary Research: Analysis of peer-reviewed literature, clinical and epidemiological studies, regulatory information from the U.S. FDA and Health Canada, company websites and filings, clinical trial databases, patent databases, funding records, and industry developments related to Type 2 diabetes therapies, including insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and other glucose-lowering treatments.
• Validation: Market estimates are triangulated through top-down and bottom-up modeling, supported by historical market values, company-level analysis, segment-level assessment, regional comparisons, and expert feedback to improve consistency and reliability.